INDEX NAME NOT YET ASSIGNED

INDEX NAME NOT YET ASSIGNED Suppliers list
Company Name: Nantong QuanYi Biotechnology Co., Ltd  
Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Products Intro: Product Name:RMC-6272
CAS:2382769-46-0
Purity:98%+ HPLC Package:10mg,500mg,1g,2g,5g,10g,more
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:RMC-6272
CAS:2382769-46-0
Package:25mg/RMB 19600
INDEX NAME NOT YET ASSIGNED Basic information
Product Name:INDEX NAME NOT YET ASSIGNED
Synonyms:RMC-6272;RM-006
CAS:2382769-46-0
MF:C95H141FN6O27S
MW:1850.25
EINECS:
Product Categories:
Mol File:2382769-46-0.mol
INDEX NAME NOT YET ASSIGNED Structure
INDEX NAME NOT YET ASSIGNED Chemical Properties
density 1.28±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
pka10.40±0.70(Predicted)
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
INDEX NAME NOT YET ASSIGNED Usage And Synthesis
Biological ActivityRMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors[1]. RMC-6272 shows more effective growth inhibition in multiple TSC1 or TSC2 mutant tumor cell lines compared to Rapamycin. RMC-6272 causes a more profound growth inhibition in the TSC1 or TSC2 mutant cells than the wild type cells. RMC-6272 at ~1 nM shows near complete inhibition of p4E-BP1T37/46, while inhibition of pS6S240/244 levels is similar for Rapamycin and RM compounds[1]. RMC-6272 markedly reduces kidney tumor burden in Tsc2+/- A/J mice after four weeks of treatment. Tumor regrowth is assessed two months after treatment cessation, tumor burden is significantly reduced in the RMC-6272 group as compared to the Rapamycin and MLN0128 groups[1].
References[1]. Heng Du, et al. Bi-steric mTORC1-selective inhibitors demonstrate improved potency and efficacy in tumors with mTORC1 hyperactivation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1026.
INDEX NAME NOT YET ASSIGNED Preparation Products And Raw materials
Tag:INDEX NAME NOT YET ASSIGNED(2382769-46-0) Related Product Information